Phase 4 clinical trial software for post-marketing studies

Phase 4 is the stage after a product is authorised. The studies take several shapes: interventional trials that extend the evidence base, post-authorisation safety studies, observational cohorts that watch how a product performs in routine care, registries, and studies that fulfil a post-marketing requirement or commitment agreed with a regulator. The sponsor might be a large company, a small biotech that has just brought a product to market, or an academic or medical-society group with a safety question.

The common thread is scale and duration rather than intensity. A pivotal trial might see participants weekly in a clinic. A post-marketing study might ask for a short visit every six months for three years, with questionnaires in between and adverse events reported as they occur. Dropouts and loss to follow-up are the main data quality risk, so keeping contact easy is the main design problem. That is why the right software looks different: it should make a long schedule cheap to run, make participant input effortless and keep every change auditable over years.

For the closely related world of observational designs see EDC for observational studies, EDC for registry studies and EDC for real-world evidence studies. Device-specific follow-up is covered on the post-market clinical studies page.

Safety is the reason many Phase 4 studies exist, so the adverse event workflow matters. Capture has an adverse event form with the minimum dataset, an AESI form for events of special interest, and an SAE workflow with sign-off. Because every field carries its own audit trail, you can show how an event record developed, who changed what and why. See adverse event reporting software for the detailed workflow.

It is important to be clear about scope. Capture captures adverse events inside a study. It is not a pharmacovigilance case management system, and it does not replace a safety database for medical coding, aggregate reporting or regulatory submissions. Many sponsors run both: the EDC for protocol-defined data capture and a dedicated safety system for case processing, with a defined process to reconcile between them. If your commitment study has formal reporting obligations, plan that reconciliation at design time, not at database lock.

A post-marketing study that supports a regulatory commitment can be reviewed years after it began, so the paper trail has to hold up. The audit trail in Capture is written by database triggers, one row per changed field, and it cannot be modified through the interface. Clinical data is soft-deleted only. Electronic signatures re-authenticate the signer and are linked to the exact content signed. These are 21 CFR Part 11-aligned controls; the sponsor remains responsible for validated, documented use, which is covered in the computer system validation guide.

Because a Phase 4 study can last longer than a typical vendor evaluation cycle, think about portability at the start. Data exports with a data dictionary and audit trails are available, and the data ownership and portability page sets out what to ask any vendor. Data is hosted in the EU (Frankfurt) or the USA (N. Virginia), which helps when participants and sites sit in one region.

Two honest notes on fit. Capture suits sponsors that run their own data capture with a small team. If a study needs a validated SDTM export from the system itself, check current documentation first, since Capture labels templates with SDTM domains rather than claiming a validated transformation. And if your sponsor or CRO mandates a specific EDC, that system will be used for the study.